Log in

NASDAQ:ETON - Eton Pharmaceuticals Stock Price, Forecast & News

-0.21 (-3.24 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
Now: $6.28
50-Day Range
MA: $6.02
52-Week Range
Now: $6.28
Volume44,666 shs
Average Volume67,921 shs
Market Capitalization$111.85 million
P/E RatioN/A
Dividend YieldN/A
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ETON



Sales & Book Value

Annual SalesN/A
Book Value$1.49 per share


Net Income$-12,740,000.00


Market Cap$111.85 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals Inc (NASDAQ:ETON) issued its earnings results on Thursday, November, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. View Eton Pharmaceuticals' Earnings History.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Eton Pharmaceuticals.

What price target have analysts set for ETON?

3 brokers have issued 1 year price targets for Eton Pharmaceuticals' stock. Their forecasts range from $13.50 to $21.00. On average, they expect Eton Pharmaceuticals' stock price to reach $17.25 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price. View Analyst Price Targets for Eton Pharmaceuticals.

What is the consensus analysts' recommendation for Eton Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eton Pharmaceuticals.

What are Wall Street analysts saying about Eton Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eton Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois. " (12/11/2019)
  • 2. HC Wainwright analysts commented, "We have valued Eton based on a DCF assessment, driven by three candidates in the company’s pipeline, namely and ET-202. Our valuation approach utilizes a 12% discount rate and 2% terminal growth rate, along with a 28% effective tax rate applied to future cash flows." (8/5/2019)

Has Eton Pharmaceuticals been receiving favorable news coverage?

News stories about ETON stock have been trending very positive this week, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Eton Pharmaceuticals.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Opko Health (OPK), Amarin (AMRN), Clovis Oncology (CLVS), Cronos Group (CRON), eHealth (EHTH), Rhythm Pharmaceuticals (RYTM), TrovaGene (TROV), Bristol-Myers Squibb (BMY) and Myovant Sciences (MYOV).

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the folowing people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Allied Advisory Services Inc. (0.20%) and First Trust Advisors LP (0.14%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Institutional Ownership Trends for Eton Pharmaceuticals.

Which institutional investors are buying Eton Pharmaceuticals stock?

ETON stock was purchased by a variety of institutional investors in the last quarter, including First Allied Advisory Services Inc. and First Trust Advisors LP. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman. View Insider Buying and Selling for Eton Pharmaceuticals.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $6.28.

How big of a company is Eton Pharmaceuticals?

Eton Pharmaceuticals has a market capitalization of $111.85 million. The company earns $-12,740,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.View Additional Information About Eton Pharmaceuticals.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is http://www.etonpharma.com/.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

MarketBeat Community Rating for Eton Pharmaceuticals (NASDAQ ETON)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote "Outperform" if you believe ETON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel